Dutogliptin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Dutogliptin
Accession Number
DB11723
Description

Dutogliptin has been investigated for the treatment of Diabetes Mellitus, Type II.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 241.1
Monoisotopic: 241.159772
Chemical Formula
C10H20BN3O3
Synonyms
Not Available
External IDs
  • PHX1149

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action

Dutogliptin is a potent and selective inhibitor of DPP4, a serine protease that has emerged as an important target for the treatment of type 2 diabetes. Inhibiting DPP4 increases the physiological levels of regulatory peptides, such as GLP-1, an important modulator of insulin response and digestion.

TargetActionsOrganism
UDipeptidyl peptidase 4Not AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life

10-13 hours

Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcarboseThe risk or severity of hypoglycemia can be increased when Acarbose is combined with Dutogliptin.
AcebutololThe therapeutic efficacy of Dutogliptin can be increased when used in combination with Acebutolol.
AcetazolamideThe therapeutic efficacy of Dutogliptin can be increased when used in combination with Acetazolamide.
AcetohexamideDutogliptin may increase the hypoglycemic activities of Acetohexamide.
Acetyl sulfisoxazoleThe therapeutic efficacy of Dutogliptin can be increased when used in combination with Acetyl sulfisoxazole.
Acetylsalicylic acidThe risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Dutogliptin.
AlbiglutideThe risk or severity of hypoglycemia can be increased when Albiglutide is combined with Dutogliptin.
AlclometasoneThe risk or severity of hyperglycemia can be increased when Alclometasone is combined with Dutogliptin.
AlogliptinThe risk or severity of angioedema can be increased when Alogliptin is combined with Dutogliptin.
AlteplaseThe risk or severity of angioedema can be increased when Alteplase is combined with Dutogliptin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Product Ingredients
IngredientUNIICASInChI Key
Dutogliptin Tartrate79QH89EV9M890402-81-0SVWHNLVZPGXBNS-MHDNXTQBSA-N

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Alpha amino acid amides
Alternative Parents
N-acylpyrrolidines / Tertiary carboxylic acid amides / Boronic acids / Organic metalloid salts / Dialkylamines / Azacyclic compounds / Organic oxides / Monoalkylboranes / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Aliphatic heteromonocyclic compound / Alkylborane / Alpha-amino acid amide / Amine / Azacycle / Boronic acid / Boronic acid derivative / Carbonyl group / Carboxamide group / Hydrocarbon derivative
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
38EAO245ZX
CAS number
852329-66-9
InChI Key
DVJAMEIQRSHVKC-BDAKNGLRSA-N
InChI
InChI=1S/C10H20BN3O3/c15-10(7-13-8-3-4-12-6-8)14-5-1-2-9(14)11(16)17/h8-9,12-13,16-17H,1-7H2/t8-,9+/m1/s1
IUPAC Name
[(2R)-1-(2-{[(3R)-pyrrolidin-3-yl]amino}acetyl)pyrrolidin-2-yl]boronic acid
SMILES
OB(O)[[email protected]@H]1CCCN1C(=O)CN[[email protected]@H]1CCNC1

References

General References
  1. O'Farrell AM, van Vliet A, Abou Farha K, Cherrington JM, Campbell DA, Li X, Hanway D, Li J, Guler HP: Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects. Clin Ther. 2007 Aug;29(8):1692-705. [PubMed:17919550]
PubChem Compound
11253490
PubChem Substance
347828085
ChemSpider
9428517
ZINC
ZINC000169746730

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentType 2 Diabetes Mellitus1
3TerminatedTreatmentImpaired kidney function / Type 2 Diabetes Mellitus1
3TerminatedTreatmentType 2 Diabetes Mellitus6
2CompletedTreatmentType 2 Diabetes Mellitus1
2Enrolling by InvitationTreatmentAcute Myocardial Infarction (AMI) / Acute Myocardial Ischemia / ST Elevation Myocardial Infarction (STEMI)1
2TerminatedTreatmentType 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility6.93 mg/mLALOGPS
logP-1.1ALOGPS
logP-2.4ChemAxon
logS-1.5ALOGPS
pKa (Strongest Acidic)8.63ChemAxon
pKa (Strongest Basic)10.1ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area84.83 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity58.91 m3·mol-1ChemAxon
Polarizability25.94 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Virus receptor activity
Specific Function
Cell surface glycoprotein receptor involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation. Acts as a positive regulator of T-cell coactivation, by bindi...
Gene Name
DPP4
Uniprot ID
P27487
Uniprot Name
Dipeptidyl peptidase 4
Molecular Weight
88277.935 Da

Drug created on October 20, 2016 14:42 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates